Secukinumab,Adalimumab
abbvie,novartis
[]
l15 #acr22 surpass: sec vs bsada (sdz-adl) on radiographic progression of as
p3b: sec 150 mg v sec 300 v sdz-adl
wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance
hard to assess as overall, low rate of progression 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land